摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-benzyloxy-5-((S)-2-chloro-1-hydroxy-ethyl)-1H-quinolin-2-one | 312753-75-6

中文名称
——
中文别名
——
英文名称
8-benzyloxy-5-((S)-2-chloro-1-hydroxy-ethyl)-1H-quinolin-2-one
英文别名
5-[(1S)-2-chloro-1-hydroxyethyl]-8-phenylmethoxy-1H-quinolin-2-one
8-benzyloxy-5-((S)-2-chloro-1-hydroxy-ethyl)-1H-quinolin-2-one化学式
CAS
312753-75-6
化学式
C18H16ClNO3
mdl
——
分子量
329.783
InChiKey
ZKCIIJWVIAWIJD-OAHLLOKOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Scalable Ruthenium-Catalyzed Asymmetric Synthesis of a Key Intermediate for the β2-Adrenergic Receptor Agonist
    作者:Masato Komiyama、Takahiro Itoh、Takumi Takeyasu
    DOI:10.1021/op500338d
    日期:2015.1.16
    enantioselective and robust synthetic process to obtain a useful intermediate for the β2-adrenergic receptor agonist is described. Asymmetric transfer hydrogenation of ketone 1c by (S,S)-3b (Ms-DENEB) afforded chiral alcohol 2c in 71% isolated yield and 99% ee. The deprotection completed the synthesis of (R)-5 in 41% overall yield from 1b, which is readily commercially available.
    描述了对映选择性和鲁棒的合成方法,以获得β2-肾上腺素能受体激动剂的有用中间体。酮的不对称转移氢化1C由(小号,小号) -图3b(MS-DENEB),得到手性醇2C在71%分离产率和99%的ee值。脱保护以1b的总收率完成了(R)-5的合成,总产率为41%,这很容易商购。
  • [EN] BETA2-ADRENOCEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE
    申请人:NOVARTIS AG
    公开号:WO2000075114A1
    公开(公告)日:2000-12-14
    Compounds of formula (I) in free or salt or solvate form, where Ar is a group of formula (II) Y is carbon or nitrogen and R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10¿, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. The compounds of formula (I) in free, salt or solvate form, have β2-adrenoreceptor agonist activity.
    公式(I)的化合物,其自由形式、盐形式或溶剂化合物形式中,其中Ar是公式(II)的基团,Y是碳或氮,R?1,R2,R3,R4,R5,R6,R7,R8,R9,R10,X,n,p,q和r如规范所定义,它们的制备以及它们作为药物的用途,特别是用于治疗阻塞性或炎性呼吸道疾病。公式(I)的化合物在自由、盐或溶剂化合物形式中具有β2-肾上腺素受体激动剂活性。
  • BETA-2-ADRENORECEPTOR AGONISTS
    申请人:Cuenoud Bernard
    公开号:US20100029705A1
    公开(公告)日:2010-02-04
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    该化合物的化学式为自由或盐或溶剂形式,其中Ar是化学式的一组,Y是碳或氮,R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在说明书中,其制备以及其作为药物的用途,特别是用于治疗阻塞性或炎症性呼吸道疾病。
  • β2-adrenoceptor agonists
    申请人:Novartis AG
    公开号:US07622483B2
    公开(公告)日:2009-11-24
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    公式为自由或盐或溶剂化合物,其中Ar是公式的一组,Y为碳或氮,而R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r如规范中所定义,其制备和用途作为药物,特别是用于治疗阻塞性或炎症性呼吸道疾病。
  • Beta-2-adrenoreceptor agonists
    申请人:Novartis AG
    公开号:US08067437B2
    公开(公告)日:2011-11-29
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    该化合物的分子式为自由或盐或溶剂形式,其中Ar是公式的一组,Y是碳或氮,R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义如规范所述,其制备和用途作为药物,特别是用于治疗阻塞性或炎症性呼吸道疾病。
查看更多